Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598674 | 1.00 | FPR3 (0.53) | FPR3FPR2PRMT5HCRTR2HCRTR1 | |
| SCHEMBL1874931 | 0.86 | FPR3 (0.47) | FPR3FPR2PRMT5OPRK1KMT2A | |
| SCHEMBL1878430 | 0.86 | FPR3 (0.47) | FPR3FPR2PRMT5OPRK1KMT2A | |
| SCHEMBL12810103 | 0.86 | FPR3 (0.49) | FPR3FPR2PRMT5HCRTR2HCRTR1 | |
| SCHEMBL8007405 | 0.86 | HCRTR2 (0.60) | FPR3FPR2PRMT5HCRTR2HCRTR1 | |
| SCHEMBL22761842 | 0.86 | HCRTR1 (0.55) | HCRTR2HCRTR1DPP4 | |
| SCHEMBL1598401 | 0.85 | DPP4 (0.55) | FPR3FPR2PRMT5HCRTR1USP30 | |
| SCHEMBL1598400 | 0.85 | DPP4 (0.55) | FPR3FPR2PRMT5HCRTR1USP30 | |
| SCHEMBL12810104 | 0.84 | FPR2 (0.62) | FPR3FPR2PRMT5OPRK1KMT2A | |
| SCHEMBL15254298 | 0.83 | IKBKB (0.46) | FPR3FPR2PRMT5KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | FPR3 674/4885FPR2 824/4885PRMT5 200/4885 |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | FPR3 3154/4885FPR2 4049/4885PRMT5 1634/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | FPR3 674/4885FPR2 824/4885PRMT5 200/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | FPR3 674/4885FPR2 824/4885PRMT5 200/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | FPR3 223/4885FPR2 443/4885PRMT5 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.